Development of an Electronic Medical Record-Based Score for Heart Failure Prediction in Cancer Survivors

基于电子病历的癌症幸存者心力衰竭预测评分系统的开发

阅读:1

Abstract

BACKGROUND: Awareness of heart failure (HF) as a long-term complication of cancer has led to an interest in HF surveillance among survivors. However, existing HF risk scores are not tailored for survivors and not designed for the use in electronic medical records (EMRs) or administrative data sets where clinical data such as blood pressure and pathology results are often unavailable. OBJECTIVES: The objective of the study is to develop a cancer-specific incident HF risk score suitable for screening in EMR or administrative data sets. METHODS: The cancer-specific HF prediction from EMRs in survivor health care (CHERISH) risk score was developed from risk variables identified in 16,191 cancer survivors (mean 61 years; 59.5% female) derived from the UK Biobank. External validation was conducted in a population-based Ontario cohort (n = 446,096; mean 67 years; 53.9% female). HF risk classification with CHERISH was compared against the ARIC (Atherosclerotic Risk In Community)-HF score using area under the curve (AUC). RESULTS: The CHERISH score incorporates 11 clinical variables-age, years since cancer diagnosis, coronary heart disease, arrhythmia, myocardial infarct, diabetes, hypertension, leukemia, non-Hodgkin lymphoma, lung cancer, and breast cancer. CHERISH demonstrated strong prediction of 10-year HF incidence during internal validation (AUC: 0.829), exceeding ARIC-HF (AUC: 0.697; P < 0.001). In external validation, CHERISH showed an AUC of 0.721 in predicting 10-year HF incidence, compared to an AUC of 0.751 (P < 0.001) with ARIC-HF. CONCLUSIONS: The integration of the CHERISH score into EMR systems may provide large-scale, automated HF risk assessment in cancer survivors, using routinely collected clinical data.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。